Additionally, blockade of P2X7 receptor signaling may reduce hippocampal amyloid plaques in AD; regenerate dopaminergic neurons of nigrostriatal pathway in PD; delay the ALS onset, progression, and motor performance; decrease MS-related symptoms and microglial activation in this condition; exhibit anti-depressant properties; reduce features related to mania; and decrease tumor growth. This evidence concerns the gene P2RX7 and myeloid sarcoma.